| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 08.02.
| Watch for Continued Gains in Shares of Novo Nordisk | | 18 | SmarTrend |
| 08.02.
| 500% Kursplus mit Novo Nordisk | | 184 | STOCK-WORLD.de |
| Der dänische Insulinspezialist Novo Nordisk gab Anfang Februar seine Geschäftszahlen für das Jahr 2011 bekannt und diese fielen einmal mehr sehr gut aus. Auch der Ausblick auf das Jahr 2012 fiel ...Den...
Mehr lesen zu:
500% Kursplus mit Novo Nordisk | |
| 07.02.
| Shares of Novo Nordisk Rise to a New 52-Week High | | 24 | SmarTrend |
| 07.02.
| Novo Nordisk A/S: Novo Nordisk's Annual Report 2011 | | 56 | GlobeNewswire |
| Financial, social and environmental performance
Bagsværd, Denmark, 2012-02-07 11:58 CET (GLOBE NEWSWIRE) --
This is Novo Nordisk's detailed annual report for 2011.
Anne Margrethe HaugeAtt...
Mehr lesen zu:
Novo Nordisk A/S: Novo Nordisk's Annual Report 2011 | |
| 06.02.
| Novo Nordisk Posts Solid 4Q | | 29 | Zacks |
| 02.02.
| Novo Nordisk posts $3.95 bln profit for 2011, expects strong growth in 2012 | | 66 | Xinhuanet |
| 02.02.
| Novo Nordisk Reports 19% Rise In Q4 Profit, Lifts Forecast | | 24 | Benzinga.com |
| 02.02.
| Danish drug maker Novo Nordisk's Q4 profits soar 19 per cent, outlook is raised | | 13 | Yahoo-CAN |
| 02.02.
| Danish drug maker Novo Nordisk's profits soar, outlook is raised | | 10 | Yahoo-CAN |
| 02.02.
| Danish drug maker Novo Nordisk's 4Q profits soar 19 per cent, outlook is raised | | 15 | Yahoo-CAN |
| 02.02.
| Novo Nordisk results soar on diabetes drug sales | | 11 | Yahoo-USA |
| 02.02.
| Novo Nordisk Q4 profits jump, outlook raised | | 32 | Yahoo-USA |
| 28.01.
| And They're Off: Amylin And Novo Nordisk Begin Their Battle | | 60 | Forbes |
| 23.01.
| Novo Nordisk Establishes Type 1 Diabetes R&D Center in Seattle | | 61 | PR Newswire |
| PRINCETON, N.J., Jan. 23, 2012 /PRNewswire/ -- Novo Nordisk (NYSE:NVO) announced today that the company will establish a type 1 diabetes research and development center in Seattle, Wash....
Mehr lesen zu:
Novo Nordisk Establishes Type 1 Diabetes R&D Center in Seattle | |
| 19.01.
| Novo Nordisk Named to FORTUNE'S '100 Best Companies to Work For' List for Fourth Consecutive Year | | 65 | PR Newswire |
| PRINCETON, N.J., Jan. 19, 2012 /PRNewswire/ -- Novo Nordisk (NYSE: NVO), the world leader in diabetes care, has been ranked 43rd in FORTUNE magazine's 2012 "100 Best Companies to Work...
Mehr lesen zu:
Novo Nordisk Named to FORTUNE'S '100 Best Companies to Work For' List for Fourth Consecutive Year | |
| 17.01.
| Novo Nordisk Partners with Paula Deen and Sons, Bobby and Jamie Deen, on National Diabetes Initiative | | 39 | PR Newswire |
| PRINCETON, N.J., Jan. 17, 2012 /PRNewswire/ -- Novo Nordisk, the world leader in diabetes care, is teaming up with American cooking stars Paula Deen and her sons, Bobby and Jamie Deen, to launch Diabetes...
Mehr lesen zu:
Novo Nordisk Partners with Paula Deen and Sons, Bobby and Jamie Deen, on National Diabetes Initiative | |
| 13.01.
| Novo Nordisk Bearish Moving Average Crossover Alert | | 17 | SmarTrend |
| 13.01.
| Novo Nordisk: Increasing Diabetes Rate Should Benefit This Danish Pharmaceutical | | 7 | Seeking Alpha |
| 04.01.
| Citigroup belässt Novo Nordisk auf 'Buy' - Ziel 715 dänische Kronen | | 244 | APA-dpa-AFX-Analyser |
| Die Citigroup hat die Einstufung für
Novo Nordisk auf "Buy" mit einem Kursziel von 715,00 dänischen
Kronen belassen. Die neue Formulierung des Diabetes-Medikaments
Lantus von Sanofi scheine zwar...
Mehr lesen zu:
Citigroup belässt Novo Nordisk auf 'Buy' - Ziel 715 dänische Kronen | |
| 16.12.
| CBio - Update Novo Nordisk Option Agreement | | 15 | wotnews |
